FLT3 and hematopoietic and lymphoid cell neoplasm: Indeed, the concomitant blockade of Fms-like tyrosine kinase 3 (FLT3) using Quizartinib (a tyrosine kinase inhibitor) and MA by means of small molecules (C43 or TAK-165) identified in a functional screen triggered HK2 degradation and metabolic catastrophe in solid and hematopoietic cancer cells [32,91].